Dr David Urech
Numab is a Swiss biotech company focusing on the discovery and development of therapeutic antibodies. Numab is a young company lead by a Management with proven track record in the biotech industry.
Numab applies a high-throughput selection system that increases the antibody discovery success rates by magnitudes and allows to efficiently identify best-in-class and/or first in class antibodies. The discovery engine is particularly well suited to detect antibodies against unconventional targets such as multi-spanning transmembrane proteins (e.g. GPCRs or ion channels).
Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, however, also applies its breakthrough technology to discover highly potent antibodies on behalf of its partners in the pharmaceutical industry.
